First-line treatment with ibrutinib + venetoclax provides deep responses in patients with CLL
In this MEDtalk Paolo Ghia, Professor, President of the European Research Initiative on CLL, presents the results of the CAPTIVATE study. The combination of ibrutinib and venetoclax is an all-oral, once-daily, chemotherapy-free regimen that provides deep responses. The data from the study support the potential for treatment-free remission with fixed-duration treatment, including in patients with high-risk features.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.